Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of NZ700301ApublicationCriticalpatent/NZ700301A/en
Measuring Or Testing Involving Enzymes Or Micro-Organisms
(AREA)
Investigating Or Analysing Biological Materials
(AREA)
Abstract
Disclosed is the use of bevacizumab in the preparation of a medicament for improving the progression-free survival of a patient suffering from metastatic colorectal cancer, wherein the medicament is for administration to the patient in combination with a chemotherapy regimen, and wherein the patient has been determined to have an increased level of VEGFA relative to control levels determined in patients diagnosed with metastatic colorectal cancer.
NZ700301A2010-01-192011-01-18Tumor tissue based biomarkers for bevacizumab combination therapies
NZ700301A
(en)
methods for controlling the dosage of an antitumor drug administered to a cancer patient, for administering at least one antitumor drug in two separate doses in a cancer patient and for selecting at least one antitumor drug